relcovaptan
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Oxytocin receptorANTAGONIST
OXTR antagonist
- Vasopressin V1a receptorANTAGONIST
AVPR1A antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3[C@](O)(c3ccccc3Cl)[C@@H]2C(=O)N2CCC[C@H]2C(N)=O)cc1OC- Mol. weight
- 620.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL419667 ↗
Also known as
- 1-(5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1h-indole-2-carbonyl)pyrrolidine-2-carboxamide
- 2-pyrrolidinecarboxamide, 1-((5-chloro-3-(2-chlorophenyl)-1-((3,4-dimethoxyphenyl)sulfonyl)-2,3-dihydro-3-hydroxy-1h-indol-2-yl)carbonyl)-, (2r-(2alpha(s*),3beta))-
- relcovaptan
- relcovaptan
- relcovaptan
- sr 49059
- sr-49059
- sr-49059
- sr-49059
- tdi-0134
- tdi-0134